ORIC PHARMACEUTICALS, INC. Earnings Per Share, Basic and Diluted
ORIC PHARMACEUTICALS, INC. (ORIC) reported Earnings Per Share, Basic and Diluted of -$0.59 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-09.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-09
- ORIC PHARMACEUTICALS, INC. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.59.
- ORIC PHARMACEUTICALS, INC. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.58.
- ORIC PHARMACEUTICALS, INC. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.47.
- ORIC PHARMACEUTICALS, INC. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.57.
- ORIC PHARMACEUTICALS, INC. earnings per share, basic and diluted for fiscal 2021 was -$2.07.
- ORIC PHARMACEUTICALS, INC. earnings per share, basic and diluted for fiscal 2020 was -$3.36.
- ORIC PHARMACEUTICALS, INC. earnings per share, basic and diluted for fiscal 2019 was -$14.15.
- ORIC PHARMACEUTICALS, INC. earnings per share, basic and diluted for fiscal 2018 was -$12.32.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$0.59 10-Q · filed 2022-05-09 | -$1.17 derived: net income ÷ weighted average shares · filed 2023-05-08 | -$1.64 derived: net income ÷ weighted average shares · filed 2023-05-08 | -$2.21 derived: net income ÷ weighted average shares · filed 2023-05-08 |
| 2021-12-31 | -$0.58 derived: net income ÷ weighted average shares · filed 2023-03-16 | -$1.05 derived: net income ÷ weighted average shares · filed 2023-03-16 | -$1.62 derived: net income ÷ weighted average shares · filed 2023-03-16 | -$2.07 10-K · filed 2022-03-21 |
| 2021-09-30 | -$0.47 10-Q · filed 2021-11-08 | -$1.04 derived: net income ÷ weighted average shares · filed 2022-11-07 | -$1.49 10-Q · filed 2021-11-08 | -$2.31 derived: net income ÷ weighted average shares · filed 2022-11-07 |
| 2021-06-30 | -$0.57 10-Q · filed 2021-08-10 | -$1.02 10-Q · filed 2021-08-10 | -$1.84 derived: net income ÷ weighted average shares · filed 2022-08-11 | -$2.66 derived: net income ÷ weighted average shares · filed 2022-08-11 |
| 2021-03-31 | -$0.45 10-Q · filed 2022-05-09 | -$1.27 derived: net income ÷ weighted average shares · filed 2022-05-09 | -$2.09 derived: net income ÷ weighted average shares · filed 2022-05-09 | -$2.66 derived: net income ÷ weighted average shares · filed 2022-05-09 |
| 2020-12-31 | -$0.84 derived: net income ÷ weighted average shares · filed 2022-03-21 | -$1.68 derived: net income ÷ weighted average shares · filed 2022-03-21 | -$2.27 derived: net income ÷ weighted average shares · filed 2022-03-21 | -$3.36 10-K · filed 2022-03-21 |
| 2020-09-30 | -$0.84 10-Q · filed 2021-11-08 | -$1.41 derived: net income ÷ weighted average shares · filed 2021-11-08 | -$2.52 10-Q · filed 2021-11-08 | -$3.85 derived: net income ÷ weighted average shares · filed 2022-03-21 |
| 2020-06-30 | -$0.51 10-Q · filed 2021-08-10 | -$1.68 10-Q · filed 2021-08-10 | -$3.31 derived: net income ÷ weighted average shares · filed 2022-03-21 | -$5.06 derived: net income ÷ weighted average shares · filed 2022-03-21 |
| 2020-03-31 | -$4.46 10-Q · filed 2021-05-06 | -$8.71 derived: net income ÷ weighted average shares · filed 2022-03-21 | -$12.08 derived: net income ÷ weighted average shares · filed 2022-03-21 | -$15.30 derived: net income ÷ weighted average shares · filed 2022-03-21 |
| 2019-12-31 | -$4.25 derived: net income ÷ weighted average shares · filed 2022-03-21 | -$7.62 derived: net income ÷ weighted average shares · filed 2022-03-21 | -$10.82 derived: net income ÷ weighted average shares · filed 2022-03-21 | -$14.15 10-K · filed 2022-03-21 |
| 2019-09-30 | -$3.36 10-Q · filed 2020-11-05 | -$6.55 derived: net income ÷ weighted average shares · filed 2020-11-05 | -$9.87 10-Q · filed 2020-11-05 | |
| 2019-06-30 | -$3.19 10-Q · filed 2020-08-05 | -$6.51 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | -$3.32 10-Q · filed 2020-05-20 | |||
| 2018-12-31 | -$12.32 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |